Gastric cancer is the fifth most frequently diagnosed cancer worldwide, behind breast, lung,
colorectal, and prostate cancers. In gastric cancer, multimodality treatment shows …

Rapid proliferation and metastasis of gastric cancer (GC) resulted in a poor prognosis in the
clinic. Previous studies elucidated that long non-coding RNA (LncRNA) LINC00205 was …

Abstract Background and Objective Perioperative chemotherapy (PC) with radical surgery
represents the gold standard of treatment for resectable advanced gastric cancer (GC). The …

Background Neoadjuvant chemotherapy (NACT) before radical gastrectomy is preferred for
locally advanced gastric cancer (GC). However, clinical practices demonstrate that a …

Aim Systemic inflammation has been associated with chemoresistance and prognosis in
solid tumors. Systemic immune‐inflammation index (SII) is a novel marker derived from …

ABSTRACT BACKGROUND: Surgical resection remains the main curative therapeutic
modality for advanced gastric cancer. Recently, the association of preoperative …

Objective Despite increasingly sophisticated medical technology, the prognosis of patients
with advanced gastric cancer is still not objectively certain. Therefore, it is urgent to identify …

Background Following neoadjuvant chemotherapy (NAC) for resectable gastric cancer, the
prognostic adequacy of the UICC staging system needs to be investigated. In particular to …

BACKGROUND Current tumor regression grade (TRG) evaluations are based on various
systems which brings confusion for oncologists and pathologists when interpreting results …

Purpose To define and predict early recurrence (ER) in patients with gastric cancer (GC)
who underwent radical gastrectomy after neoadjuvant chemotherapy (NAC). Methods The …